As of October 2026, all five regulators here have warned about or restricted retatrutide, and four name BPC-157. Every row is a regulatory fact from the regulator's own page, dated and linked.
Regulatory fact. Dots run FDA, TGA, Health Canada, MHRA, Medsafe. A filled dot means the regulator names the peptide in a warning or lists it as a prescription medicine, by name or through a group entry.
New trials, FDA changes and side-effect reports, written in plain English. Every result says whether it was tested in people or in animals.
Retatrutide is named by all 5. BPC-157, TB-500 and CJC-1295 are named by the FDA, TGA and Health Canada; New Zealand also schedules BPC-157 and TB-500. Each cell links to the notice behind it.
| Peptide | FDAUnited States | TGAAustralia | Health CanadaCanada | MHRAUnited Kingdom | MedsafeNew Zealand |
|---|---|---|---|---|---|
| BPC-157 | Named in a warning Category 2 safety risk page; 2 warning letters | Named in a warning Named in the April 2026 alert and June 2026 statement | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Prescription medicine by name Prescription medicine since 2023; analogues added as a group in 2025 |
| Retatrutide | Named in a warning Named in 21 of 29 warning letters | Named in a warning Named in the April 2026 alert and June 2026 statement | Named in a warning Named in the 2025 Canada Peptide and 2026 advisories | Named in a warning Not authorized in the UK; three 2026 releases | Prescription medicine by name Listed by name as a prescription medicine, December 2025 |
| TB-500 | Named in a warning Category 2 safety risk page; 3 warning letters | Named in a warning Named in the April 2026 alert and June 2026 statement | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Covered by a group entry Prescription medicine (Medsafe, June 2025); thymic peptide group, December 2025 |
| CJC-1295 | Named in a warning Category 2 safety risk page | Named in a warning Named in the April 2026 alert and June 2026 statement | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Not named Not named in the Medsafe notices listed here |
| GHK-Cu | Named in a warning Category 2 safety risk page, injectable form only | Named in a warning Named in the April 2026 alert and June 2026 statement | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Not named Not named in the Medsafe notices listed here |
| Melanotan II | Named in a warning Category 2 safety risk page | Not named Not named in the TGA notices listed here | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Not named Not named in the Medsafe notices listed here |
| MOTS-c | Named in a warning Category 2 safety risk page | Not named Not named in the TGA notices listed here | Named in a warning Named in the 2025 Calgary and 2026 advisories | Not named No MHRA notice naming it found | Covered by a group entry Mitochondria-derived peptide group, December 2025 |
| Epitalon | Named in a warning Category 2 safety risk page; 1 warning letter | Not named Not named in the TGA notices listed here | Named in a warning Named in all three advisories | Not named No MHRA notice naming it found | Covered by a group entry Pineal gland peptide group, December 2025 |
"Not named" means none of the notices in this table names the peptide. It does not mean the peptide is legal to sell there: Health Canada and the TGA both say their lists are examples and that other unapproved peptides are covered too.
Newest first. Each row gives the date, the regulator, the document title as the regulator wrote it, the peptides named and what it says, with a link to the regulator's page. Filter by regulator, or link to a row by its anchor, such as #n-tga-alert-2026.
| Date | Regulator and notice | Peptides named | What it says |
|---|---|---|---|
| Oct 15, 2026 | MHRA, United Kingdom Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police Enforcement Read it on the regulator's site |
| On October 14, 2026, officers seized over 12,000 fake retatrutide and tirzepatide pens at an industrial unit in Birmingham. The MHRA says retatrutide sold outside clinical trials is supplied illegally. |
| Aug 24, 2026latest of 29 letters, 2021 to 2026 | FDA, United States Warning letters naming peptides (29 letters, tracked by Staate) Enforcement See every letter, dated |
| FDA has posted 29 warning letters that name a peptide sold online or compounded without approval, 21 of them naming retatrutide. Staate reads each letter on fda.gov and keeps the dated list. |
| Jul 24, 2026 | MHRA, United Kingdom No summer shortcut for safe weight loss Safety alert Read it on the regulator's site |
| Retatrutide has not been authorized for use in the UK, so anyone selling it is doing so illegally, and there is no guarantee a product sold as retatrutide contains it. |
| Jun 19, 2026 | TGA, Australia Concerns regarding the public health risks associated with unapproved peptide products Statement Read it on the regulator's site |
| A joint statement from Australia's health leaders, published on health.gov.au and the TGA website. Reports to the TGA and state hospital data identified liver damage, severe allergic reactions requiring hospitalization, and inflammation needing medical care. |
| May 29, 2026 | MHRA, United Kingdom Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines Enforcement Read it on the regulator's site |
| MHRA officers recovered around 12,000 doses of unlicensed weight-loss medicines from a country estate near Northampton on May 28, 2026, the agency's largest seizure of its kind. Two men were arrested under the Human Medicines Regulations 2012. |
| Apr 22, 2026page last updated | FDA, United States Certain bulk drug substances for use in compounding that may present significant safety risks Safety alert Read it on the regulator's site |
| FDA lists peptides nominated for pharmacy compounding with the safety risks it found, most often immunogenicity and peptide-related impurities. The nominations for these peptides were later withdrawn, and the page keeps them in a separate list. |
| Apr 9, 2026 | TGA, Australia Understanding your responsibilities when importing, compounding and supplying unapproved peptide products Safety alert Read it on the regulator's site |
| Unapproved peptide products have not been evaluated by the TGA for safety, quality or effectiveness. A "research use only" disclaimer does not make supply lawful, and imports labeled only with codes will not be released under the Personal Importation Scheme. |
| Apr 9, 2026 | Health Canada, Canada Think twice before injecting peptides bought online: unauthorized products can seriously harm you Public advisory Read it on the regulator's site |
| Unauthorized drug products are illegal in Canada, and a "For Research Use Only, Not for Human Consumption" label does not make them legal. Health Canada says it is working with the Canada Border Services Agency to stop shipments. |
| Dec 17, 2025 | Medsafe, New Zealand Classification of Medicines (New Zealand Gazette 2025-go7397) Classification Read it on the regulator's site |
| The prescription medicines schedule lists ten peptide group entries, among them BPC-157 analogues, thymic peptide hormones, mitochondria-derived peptides and pineal gland peptides, plus retatrutide by name. Medsafe asked for the groups in June 2025 after intercepting peptides at the border. |
| Aug 1, 2025 | Health Canada, Canada Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks Public advisory Read it on the regulator's site |
| Health Canada seized unauthorized injectable peptides sold on a company website. It states that injectable peptides are regulated as prescription drugs in Canada and that selling unauthorized drugs is illegal. |
| Apr 1, 2025 | Health Canada, Canada Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks Public advisory Read it on the regulator's site |
| Health Canada seized injectable peptides from a Calgary clinic and said none were authorized, so they are illegal to sell in Canada. People who received an injection there and have health concerns are told to see a physician, nurse practitioner or pharmacist. |
| Aug 31, 2023 | Medsafe, New Zealand Classification of Medicines (New Zealand Gazette 2023-go4130) Classification Read it on the regulator's site |
| BPC-157 is listed as a prescription medicine. The Medicines Classification Committee recommended it on May 25, 2023, after Medsafe found people importing BPC-157 for personal use. |
The CSV holds every notice with its date, regulator, country, type, title, the peptides named, a summary, the regulator's link and the check date.
Staate. "Peptide notices from five medicine regulators." Last checked October 22, 2026. https://staate.co/peptides/guides/legal-status/international/
<iframe src="https://staate.co/embed/peptide-regulator-warnings/" title="Peptide warnings from five medicine regulators, by Staate" width="100%" height="640" loading="lazy" style="border:1px solid #d9e4df;border-radius:12px;max-width:100%"></iframe> <p style="font:13px/1.5 sans-serif;margin:6px 0 0">Source: <a href="https://staate.co/peptides/guides/legal-status/international/">Staate, peptide warnings from the FDA, TGA, Health Canada, MHRA and Medsafe</a></p>
What each regulator says about selling, importing and prescribing BPC-157 and other unapproved peptides differs. Each answer below links the notice it comes from.
Unapproved peptide products are not on the Australian Register of Therapeutic Goods, and the TGA says a "research use only" disclaimer does not make supplying them lawful.
People importing for themselves must meet every condition of the Personal Importation Scheme, including a prescription when one is required. Vials labeled only with a code, or without the active ingredient and strength, will not be released. State and territory laws can add more controls.
The noticeInjectable peptides are regulated as prescription drugs in Canada, and selling an unauthorized one is illegal.
Health Canada tells people to buy prescription drugs only from licensed pharmacies and to look for an eight-digit Drug Identification Number (DIN) on the label. It has seized peptides from a Calgary clinic and from an online seller, and works with the Canada Border Services Agency to stop shipments.
The noticeBPC-157 has been a prescription medicine in New Zealand since a Gazette notice dated August 31, 2023. A notice dated December 17, 2025 lists ten peptide groups as prescription medicines.
Before a peptide is scheduled, Medsafe has no grounds under the Medicines Act 1981 to seize it at the border; it releases the parcel with a high-risk medicine letter. Medsafe intercepted 56 parcels of peptides or SARMs between April 1 and May 19, 2025, which led to the group entries.
The noticeThe MHRA says retatrutide is not authorized in the UK and anyone selling it does so illegally. We found no MHRA notice that names BPC-157.
The MHRA's 2026 releases are about weight-loss drugs: seizures of unlicensed and fake medicines, including retatrutide and tirzepatide, near Northampton and in Birmingham. The May 2026 release also mentions "peptide products" without naming them.
The noticeNo FDA-approved drug contains BPC-157, and FDA lists it with other peptides on its page of compounding substances that may present significant safety risks.
FDA has also sent 29 warning letters that name peptides sold online or compounded without approval. The full US picture, including the July 2026 advisory committee votes, is on the peptide legal status guide.
The noticeThis page reports what regulators have published. It is not legal advice, and it does not cover personal possession or state, provincial or territory law; ask a lawyer where you live.
Not in Australia or Canada. Both regulators say so in their 2026 notices, and FDA rejects the same label in its US warning letters.
The TGA's April 2026 alert says a "research use only" disclaimer does not change a product's regulatory status, does not permit importation and does not remove advertising or supply obligations. It adds that products labeled to avoid scrutiny, with ingredients left off or covered over, are unlikely to be released at the border.
Health Canada's April 2026 advisory says products marked "For Research Use Only, Not for Human Consumption" are not made legal or exempt by that labeling, and tells Canadians not to buy them. In the US, FDA quotes the same wording in its warning letters to peptide sellers and still treats the products as drugs for people.
Reports, not proof. These are adverse events reported to regulators and risks they list; a report does not show that the peptide caused the harm.
Severe allergic reactions needing adrenaline and hospital care; systemic inflammatory response syndrome; full-body itching, palpitations and sweating; insomnia, blurred vision, tiredness and joint pain; plantar fasciitis and Achilles tendinitis; unsealed packaging from an online supplier.
See the noticeLiver damage, severe allergic reactions requiring hospitalization, and inflammation and other complications needing medical attention, from TGA reports and state and territory hospital data.
See the noticeHormonal imbalance, mood swings, blood sugar imbalance, liver or kidney damage, blood clots and growth of cancerous tumors, plus infection, allergic reactions and contaminants such as heavy metals, particles or bacteria.
See the noticeFor the human trial record on BPC-157, see every BPC-157 human study. For what to watch for after an injection, see peptide side effects and red flags.
Five English-speaking regulators, public notices only. A blank cell is a fact about these documents, not about the law.
Embeddable version of the peptide-by-regulator grid added, with copy-paste code in the cite box. Same cells and check date as this page.
Table published with 12 notices from five regulators, each read on the regulator's own site. MHRA content on gov.uk searched for BPC-157, melanotan and peptide notices; none name BPC-157 or melanotan. Latest notice: October 15, 2026.
This table is rechecked each month and the date at the top changes when it is. US detail: peptide legal status guide and the BPC-157 legal status timeline. How we label evidence: editorial policy.
We email when a TGA, Health Canada, MHRA, Medsafe or FDA notice changes what this page says. Daily peptide brief, free, every source linked.